medigraphic.com
ISSN 1025-0298 (Digital)
ISSN 1025-028X (Impreso)

2021, Número 1

<< Anterior Siguiente >>

VacciMonitor 2021; 30 (1)


Método alternativo para la evaluación de la vacuna monovalente inactivada contra el virus de la fiebre aftosa

Samy-Abousenna M, Khafagy H, Abotaleb MM, Mahmoud-Darwish D, Barghooth W, Shafik N

Idioma: Ingles.
Referencias bibliográficas: 21
Paginas: 4-9
Archivo PDF: 291.06 Kb.


RESUMEN

La fiebre aftosa es una enfermedad viral altamente contagiosa de los animales de pezuña hendida que tiene un impacto económico significativo en el ganado. Se detectó un brote reciente que se registró como causado por una cepa exótica del virus de la fiebre aftosa (serotipo SAT2, topotipo VII, linaje Lib-12). La vacuna de emergencia se elaboró y evaluó in vivo, existiendo una urgente necesidad de contar con un gran número de lotes de la misma. El presente trabajo tuvo como objetivo proporcionar una evaluación rápida de la vacuna oleosa inactivada (SAT2) contra la fiebre aftosa, para excluir los lotes insatisfactorios durante circunstancias de emergencia, reduciendo tiempo, esfuerzo y costo. La extracción del contenido de antígeno de fiebre aftosa, de la vacuna oleosa adyuvada, se llevó a cabo utilizando miristato de isopropilo y alcohol bencílico. El antígeno viral extraído se identificó utilizando un ELISA de serotipificación y se cuantificó el contenido de 146S mediante análisis de gradiente de densidad de sacarosa. Las evaluaciones se realizaron de forma instantánea y a las 2h, 6h y 24h. Los resultados indicaron la eficacia del alcohol bencílico para separar la emulsión de aceite para MONTANIDE ™ ISA 206 VG o MONTANIDE ™ ISA 50 V2, mientras que el miristato de isopropilo fue eficaz para MONTANIDE ™ ISA 50 V2 únicamente.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Smith MT, Bennett AM, Grubman MJ, Bundye BC. Foot and Mouth Disease, Technical and political challenges to eradication. Vaccine.2014;32:3902-8. https://10.1016/j.vaccine.2014.04.038.

  2. OIE. Organization for Animal Health. Foot and Mouth Disease (infection with foot and mouth disease). En: OIE. World Organization for Animal Health. Manual of diagnostic tests and vaccines for terrestrial animals (mammals, birds, bees). Paris: OIE;2018.p.433-64. Available from: https://www.oie.int/.

  3. Grubman MJ, Baxt B. Foot-and-mouth disease. Clin Microbiol Rev.2004;17(2):465-93.

  4. Larskane M, Wernery U, Kinne J, Schuster R, Alexandersen G, Alexandersen S. Differences in the susceptibility of dromedary and Bactrian camels to foot and mouth disease virus. Epidemiol Infect.2009;137:549-54.

  5. Nermeen SG, Darwish DM, Abousenna MS, Galal M, Ahmed AR, Attya M, et al. Efficacy of a commercial local trivalent Foot and Mouth Disease (FMD) vaccine against recently isolated O-EA3. Inter J Vet Sci.2019;8(1):35-8. Available from: https://www.ijvets.com/pdf-files/volume-8-no-1-2019/35-38pdf.

  6. Lockhart C, Sumption K, Pino J, Lubroth J. Foot and Mouth Disease caused by serotype SAT2 in Egypt and Libya. Empress Watch.2012;25:1-7.

  7. Bazid AI, Hussein HA, Balal SS, El sanousi AA, Ahmed BM. Phylogenatic analysis of Foot and Mouth Disease virus type in Egypt 2009. Int J Virol.2014;10:28-36. doi: https://10.3923/ijv.2014.28.36.

  8. Soltan MA, Dohreig RMA, Abbas H, Ellawa M, Yousif I, Aly AE, et al. Emergence of Foot and mouth disease virus, Lib 12 lineage of topotype VII, serotype SAT2 in Egypt, 2018. Transbound Emerg Dis.2019;66:1105-6. doi: https://10.1111/tbed.13152.

  9. Scott MR, Mioulet V, Nick JK, Shirazi N, Graham J, Belsham DP. Development of tailored real-time RT-PCR assays for the detectionand differentiation of serotype O, A and Asia-1 foot-and-mouth disease virus lineages circulating in the Middle East. J Virol Methods.2014;207:146-53. doi: https://10.1016/j.jviromet.2014.07.002.

  10. Cox SJ, Voyce C, Parida S, Reid SM, Hamblin PA, Hutchings G, et al. Effect of emergency FMD vaccine antigen payload on protection, subclinical infection and persistence following direct contact challenge of cattle.Vaccine.2006;4:3184-90.

  11. Pay TW, Hingley PJ. Correlation of 140S antigen dose with the serum neutralizing antibody response and the level of protection induced in cattle by foot-and-mouth disease vaccines. Vaccine.1987;5(1):60-4.

  12. Maas RA, Komen M, van Diepen M, Oei HL, Claassen IJ. Correlation of haemagglutinin-neuraminidase and fusion protein content with protective antibody response after immunisation with inactivated Newcastle disease vaccines. Vaccine.2003;23:3137-42.

  13. Miles AP, Saul A. Extraction and characterization of vaccine antigens from water-in-oil adjuvant formulations. In: Smales CM and James DC. Therapeutic Proteins: Methods and Protocols. Totowa, NJ: Humana Press;2005.p.293-300.

  14. Barteling SJ, Meloen RH. A simple method for the quantification of 140S particles of foot-and-mouth disease virus (FMDV). Arch Gesamte Virusforsch.1974;45(4):362-4.

  15. Doel TR. FMD vaccines. Virus Res.2003;91:81-99.

  16. Saravanan P, Iqbal Z, Selvaraj DPR, Aparna M, Umapathi V, Krishnaswamy N, Tamilselvan RP. Comparison of chemical extraction methods for determination of 146S content in foot-and-mouth disease oil-adjuvanted vaccine. J Appl Microbiol.2020;128(1):65-73. doi: https://10.1111/jam.14465.

  17. Namatovu A, Tjørnehøj K, Belsham GJ, Dhikusooka MT, Wekesa SN, Muwanika VB, et al. Characterization of foot-and-mouth disease viruses (FMDVs) from Ugandan cattle outbreaks during 2012-2013: Evidence for circulation of multiple serotypes. PloSOne.2015:10(2):e0114811. doi:https://10.1371/journal.pone.0114811.

  18. Wungak YS, Ishola OO, Olugasa BO, Lazarus DD, Ehizibolo DO, Ularamu HG. Spatial pattern of foot-and-mouth disease virus serotypes in North Central Nigeria. Vet World.2017;10(4):450-6. doi: https://10.14202/vetworld.2017.450-456.

  19. Abu-Elnaga HI, Hossam GF, Ekbal MF, Ehab EI, Mohamed Gamil, Said Zidan. Correlation between foot-and-mouth disease virus antigenic mass, titer and immune response in vaccinated sheep. Benha Veterinary Medical Journal.2015;28(2):12-9. Available from: https://www.bvmj.bu.edu.eg/issues/28-2/2.pdf.

  20. Doel TR. Optimization of the immune response to foot-and-mouth disease vaccines.Vaccine.1999;17:1767-71.

  21. Patil PK, Bayry J, Ramakrihna C, Hugar B, Misra LD, Prabhudas K, Natarajan C. Immune responses of sheep to quadrivalent double emulsion foot-and-mouth disease vaccines: Rate of development of immunity and variations among other ruminants. J Clin Microbiol. 2002;40:4367-71.




2020     |     www.medigraphic.com